Evidence map›Paper›PMID 29419390›Full record

Observational studyJournal of the American Heart Association2018

Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial.

Tymon Pol, Claes Held, Johan Westerbergh, Johan Lindbäck, John H Alexander, Marco Alings, Cetin Erol, Shinya Goto, Sigrun Halvorsen, Kurt Huber and 5 more

Registry-linked trialOpen access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of the American Heart Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00412984 (A Phase 3, Active), which is not on this map. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00412984 phase3completednot on this map

A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation

TypeinterventionalSponsorBristol-Myers SquibbRan2006 to 2011Enrolled20,976ConditionsAtrial Fibrillation, Atrial FlutterArmswarfarin, apixaban
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 83 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Blood Biomarkers and the Risk of Coronary Disease in Atrial Fibrillation.Journal of the American Heart Association · 2026
    Article
  5. Observational
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 8 countries.

Tymon PolUppsala Clinical Research Center, Uppsala University, Uppsala, Sweden tymon.pol@medsci.uu.se.
Claes HeldUppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
Johan WesterberghUppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
Johan LindbäckUppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
John H AlexanderDuke Clinical Research Institute, Duke Health, Durham, NC.
Marco AlingsWorking Group on Cardiovascular Research the Netherlands, Utrecht, The Netherlands.
Cetin ErolFaculty of Medicine, Ankara University, Ankara, Turkey.
Shinya GotoDepartment of Medicine, School of Medicine, Tokai University, Isehara, Japan.
Sigrun HalvorsenDepartment of Cardiology, Oslo University Hospital Ulleval, Oslo, Norway.
Kurt Huber3rd Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminenshopital, Vienna, Austria.
Michael HannaBristol-Myers Squibb, Princeton, NJ.
Renato D LopesDuke Clinical Research Institute, Duke Health, Durham, NC.
Witold RuzylloInstitute of Cardiology, Warsaw, Poland.
Christopher B GrangerDuke Clinical Research Institute, Duke Health, Durham, NC.
Ziad HijaziUppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
Uppsala University · SEClinical Research Institute · USAnkara University · TRBristol-Myers Squibb (United States) · USInstitute of Cardiology · PLOslo University Hospital · NOTokai University · JPUtrecht University · NLWilhelminen Hospital · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDyslipidemia is a major risk factor for cardiovascular events. The prognostic importance of lipoproteins in patients with atrial fibrillation is not well understood. We aimed to explore the association between apolipoprotein A1 (ApoA1) and B (ApoB) and cardiovascular events in patients with atrial fibrillation receiving oral anticoagulation. METHODS AND

resultsUsing data from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial, ApoA1 and ApoB plasma levels were measured at baseline in 14 884 atrial fibrillation patients. Median length of follow-up was 1.9 years. Relationships between continuous levels of ApoA1 and ApoB and clinical outcomes were evaluated using Cox models adjusted for cardiovascular risk factors, medication including statins, and cardiovascular biomarkers. A composite ischemic outcome (ischemic stroke, systemic embolism, myocardial infarction, and cardiovascular death) was used as the primary end point. Median (25th, 75th) ApoA1 and ApoB levels were 1.10 (0.93, 1.30) and 0.70 g/L (0.55, 0.85), respectively. In adjusted analyses, higher levels of ApoA1 were independently associated with a lower risk of the composite ischemic outcome (hazard ratio, 0.81;

conclusionsIn patients with atrial fibrillation on oral anticoagulation, higher levels of ApoA1 were independently associated with lower risk of ischemic cardiovascular outcomes. Investigating therapies targeting dyslipidemia may thus be useful to improve cardiovascular outcomes in patients with atrial fibrillation. CLINICAL

trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT00412984.

Indexed as

Administration, OralAgedApolipoprotein A-IApolipoprotein B-100Atrial FibrillationBiomarkersDyslipidemiasFactor Xa InhibitorsFemaleHemorrhageHumansMaleMiddle AgedMulticenter Studies as TopicPyrazolesPyridonesapixabanAPOA1 protein, humanAPOB protein, humanApolipoprotein A-IApolipoprotein B-100BiomarkersFactor Xa InhibitorsPyrazolesPyridonesatrial fibrillationbiomarkerscardiovascular diseasecerebrovascular disease/stroke

Identifiers

PMID29419390
PMCPMC5850246
OpenAlexW2792643966

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.